Your browser doesn't support javascript.
loading
Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma.
Chesney, Jason A; Ribas, Antoni; Long, Georgina V; Kirkwood, John M; Dummer, Reinhard; Puzanov, Igor; Hoeller, Christoph; Gajewski, Thomas F; Gutzmer, Ralf; Rutkowski, Piotr; Demidov, Lev; Arenberger, Petr; Shin, Sang Joon; Ferrucci, Pier Francesco; Haydon, Andrew; Hyngstrom, John; van Thienen, Johannes V; Haferkamp, Sebastian; Guilera, Josep Malvehy; Rapoport, Bernardo Leon; VanderWalde, Ari; Diede, Scott J; Anderson, James R; Treichel, Sheryl; Chan, Edward L; Bhatta, Sumita; Gansert, Jennifer; Hodi, Frank Stephen; Gogas, Helen.
Afiliación
  • Chesney JA; UofL Health-Brown Cancer Center, University of Louisville, Louisville, KY.
  • Ribas A; Jonsson Comprehensive Cancer Center at the University of California Los Angeles, Los Angeles, CA.
  • Long GV; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.
  • Kirkwood JM; Royal North Shore and Mater Hospitals, Sydney, NSW, Australia.
  • Dummer R; UPMC Hillman Cancer Center, Pittsburgh, PA.
  • Puzanov I; University Hospital of Zurich, Zurich, Switzerland.
  • Hoeller C; Roswell Park Comprehensive Cancer Center, Buffalo, NY.
  • Gajewski TF; Department of Dermatology, Medical University of Vienna, Vienna, Austria.
  • Gutzmer R; University of Chicago Medical Center, Chicago, IL.
  • Rutkowski P; Medizinische Hochschule Hannover, Hannover, Germany.
  • Demidov L; Mühlenkreiskliniken Minden, Ruhr University Bochum, Bochum, Germany.
  • Arenberger P; Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
  • Shin SJ; N.N. Blokhin Russian Cancer Research Center, Moscow, Russia.
  • Ferrucci PF; University Hospital Královské Vinohrady, Prague, Czech Republic.
  • Haydon A; Division of Oncology, Yonsei University College of Medicine, Seoul, Korea.
  • Hyngstrom J; Biotherapy of Tumors Unit, Department of Experimental Oncology, European Institute of Oncology, IRCCS, Milan, Italy.
  • van Thienen JV; Department of Medical Oncology, Alfred Hospital, Melbourne, Australia.
  • Haferkamp S; Huntsman Cancer Institute, University of Utah Health, Salt Lake City, UT.
  • Guilera JM; Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Rapoport BL; Department of Dermatology, University Hospital Regensburg, Regensburg, Germany.
  • VanderWalde A; Department of Dermatology, Barcelona University, Barcelona, IDIBAPS, CIBER de Enfermedades Raras ISCIII, Madrid, Spain.
  • Diede SJ; The Medical Oncology Centre of Rosebank, Johannesburg, South Africa.
  • Anderson JR; Department of Immunology, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa.
  • Treichel S; Department of Hematology/Oncology, West Cancer Center & Research Institute, Memphis, TN.
  • Chan EL; Merck & Co, Inc, Kenilworth, NJ.
  • Bhatta S; Merck & Co, Inc, Kenilworth, NJ.
  • Gansert J; Amgen Inc, South San Francisco, CA.
  • Hodi FS; Amgen Inc, Thousand Oaks, CA.
  • Gogas H; Amgen Inc, Thousand Oaks, CA.
J Clin Oncol ; 41(3): 528-540, 2023 01 20.
Article en En | MEDLINE | ID: mdl-35998300
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Herpesvirus Humano 1 / Viroterapia Oncolítica / Melanoma Tipo de estudio: Clinical_trials Límite: Humans Idioma: En Revista: J Clin Oncol Año: 2023 Tipo del documento: Article
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Herpesvirus Humano 1 / Viroterapia Oncolítica / Melanoma Tipo de estudio: Clinical_trials Límite: Humans Idioma: En Revista: J Clin Oncol Año: 2023 Tipo del documento: Article